Lung cancer is the most common cancer worldwide, accounting for 2.3 million people in 2021. Lung cancer comprises of two categories: a) non-small lung cancer (NSCLC) and small cell lung cancer (SCLC) (approximately 15%). Current global Lung Cancer market size of over $20B in 2021 to over $33B by 2028.

 

There is huge unmet need in treating lung cancers and hence remarkable market and growth opportunities exist for Onconox. Though short-term focus for Onconox is repurposed molecule for NSCLC, our ambition for mid-to-long term focus is novel small and/or biomolecules for NSCLC and SCLC, which opens an enormous market and growth opportunity.